Personalized Cancer Vaccine

Overview

mRNA-based individualized cancer vaccines that sequence a patient's tumor to identify unique neoantigens and manufacture a custom construct within weeks, representing a 'bench to one' manufacturing challenge and the frontier of scale-out bioprocessing. Moderna's personalized cancer vaccine represents the most demanding instance of individualized medicine in bioprocessing: the therapy sequences each patient's tumor, identifies up to 34 unique neoantigens, and produces a custom mRNA construct in six weeks — every dose unique to one patient, making each manufacturing run a complete product development cycle. The emergence of personalized cancer vaccines reframes bioprocessing from 'bench to billions' to 'bench to one,' requiring the industry to develop scale-out capacity — more, smaller batches tailored to individuals — rather than the traditional scale-up model built for large homogeneous patient populations. (Segment 1 (00:00-05:00))